About US
Contact us
-
EMA publishes list of substances monitored by lead member statesThe European Medicines Agency (EMA) has published a list of active pharmaceutical substances for which individual member states will take the lead in monitoring.Member states will be responsible for m2012/10/9
-
Brazil delays new rules for governing excipientsBrazil's national medicines regulator has pushed back the implementation of proposed new rules that would govern the manufacturing of excipients.ANVISA wants to implement a new set of good manufacturi2012/10/8
-
Colorcon offers customers to expertise in film coating formulation processesColorcon has announced a new customer access initiative for its film coating formulation and process applications to help pharma manufacturers with Quality by Design (QbD) initiatives.The company sp2012/10/8
-
BASF opens new topical formation lab in NYBASF has announced the opening of a global dermatology lab in New York where topical formations will be developed for the pharmaceutical market.Specifically, it will run research skin irritations and2012/10/8
-
FDA tries to protect public from fake Internet pharmaciesWith more Internet pharmacies showing up than the FDA can possibly police, the agency is trying a new tactic tothwart sales of fake or outdated drugs. It has launched a campaign to get the public to2012/9/29
-
Willing Russians help Big Pharma move into market thereAs Russia tries to build its drugmaking infrastructure, it is finding that its citizens are anxious to help by participating in clinical trials. The New York Times reports that while many of the t2012/9/29
-
Sanofi still under pressure to limit French job cutsCall it Sanofi arm-twisting Phase II. Having bullied Sanofi into reducing its planned cuts in France by about 1,000, a French economic development official is whaling at the company again, saying the2012/9/29
-
Bayer cancer drug races through FDA approvalFast track indeed. Only three months after granting accelerated-approval status to Bayer's blockbuster hopeful regorafenib, a treatment for colorectal cancer, FDA gave the drug its final blessing. Bay2012/9/28
-
Pharma racks up $6.6B in fraud penalties so far this yearPharma's 2012 fraud toll? $6.6 billion, says advocacy group Public Citizen. Since January 1, GlaxoSmithKline ($GSK), Johnson & Johnson ($JNJ) and other drugmakers agreed to pay that amount to se2012/9/28
-
Deadbeat Europeans owe drugmakers up to $19.5BWhat's bigger, Big Pharma or Europe's big, bad debt? These days, it's a toss up. According to a new report from the European Federation of Pharmaceutical Industries and Associations, deadbeat states2012/9/27